TOP >
News Release
> Products
2011
- 2011.09.14
- Daiichi Sankyo Receives Approval for Silodosin for the Treatment of Dysuria in China
- 2011.08.17
- FDA Approval of Zelboraf(TM) (vemurafenib) Establishes Oncology Foothold in US for Daiichi Sankyo
- 2011.07.19
- Daiichi Sankyo Launches LIXIANA(R) (edoxaban), a Direct Oral Factor Xa Inhibitor, in Japan for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery
- 2011.07.01
- NEXIUM receives first regulatory approval in Japan for the treatment of acid-related disease
- 2011.06.08
- Daiichi Sankyo Launches Memary(R) 5mg, 10mg and 20mg Tablets for the Treatment of Alzheimer’s Disease in Japan
- 2011.05.18
-
Regency Therapeutics and Daiichi Sankyo Announce Launch and Commercial Availability of SPRIX(R) (ketorolac tromethamine) Nasal Spray
- 2011.04.22
- Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA(R) (Edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery
- 2011.03.11
- Voluntary recall of hemophilus influenza type b conjugate vaccine “ActHIB(R)”
- 2011.01.21
- Daiichi Sankyo Receives Approval to Manufacture and Market Memary(R) 5mg, 10mg and 20mg Tablets for the Treatment of Alzheimer’s Disease in Japan
2010
- 2010.12.21
- Daiichi Sankyo Announces First European Approval for Sevikar HCT(R), a New Three-in-one Combination Product for the Treatment of High Blood Pressure*
- 2010.09.10
- APPELLATE COURT AFFIRMS U.S. DISTRICT COURT DECISION IN FAVOR OF DAIICHI SANKYO PATENT FOR BENICAR(R), BENICAR HCT(R), and AZOR(R)
- 2010.07.27
- FDA APPROVES TRIBENZOR™, A NEW THREE-IN-ONE COMBINATION PRODUCT FOR THE TREATMENT OF HIGH BLOOD PRESSURE
- 2010.02.15
- FDA Approves Benicar(R) for the Treatment of High Blood Pressure in Children and Adolescents aged 6-16(1)
2009
- 2009.08.03
- THE U.S. DISTRICT COURT HAS ISSUED A DECISION IN OUR FAVOR IN OUR U.S. PATENT LITIGATION REGARDING BENICAR(R), BENICAR HCT(R) AND AZOR®
2008
- 2008.11.13
- DAIICHI SANKYO EUROPE GmbH announce SEVIKAR® a new fixed dose combination treatment for essential hypertension
- 2008.06.18
- New Study Shows Benicar(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering
- 2008.06.05
-
DAIICHI SANKYO COMMENCES PATENT LITIGATION AGAINST MYLAN
AND MATRIX IN THE UNITED STATES
- 2008.05.13
-
FOREST LABORATORIES, INC. AND DAIICHI SANKYO, INC. ANNOUNCE
THE TERMINATION OF THE AZOR CO-PROMOTION AGREEMENT
- 2008.04.16
- Welchol(R) Added to the American College of Endocrinology/American Association of Clinical Endocrinologists "Road Maps to Achieve Glycemic Control in Patients with Type 2 Diabetes Mellitus"
- 2008.02.01
- Analytical Results for Women from Large Scale Clinical Trial MEGA Study Employing the Hypercholesterolemia Drug Mevalotin(R) Published
2007
- 2007.07.12
-
Amgen Grants Daiichi Sankyo Exclusive Rights to Develop and
Commercialize Denosumab in Japan
- 2007.05.22
-
Amlodipine and Olmesartan Study Results Released;
Late Breaker Presented at American Society of Hypertension
Twenty-Second Annual Scientific Meeting (ASH 2007)
First Release of Data for New Combination
- 2007.01.05
- DAIICHI SANKYO, INC. ANNOUNCES FILING OF SUPPLEMENTAL NEW DRUG APPLICATION FOR WELCHOL IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS
2006
- 2006.11.29
- DAIICHI SANKYO, INC. ANNOUNCES FILING OF NEW DRUG APPLICATION FOR AMLODIPINE BESYLATE / OLMESARTAN MEDOXOMIL COMBINATION FOR THE TREATMENT OF HYPERTENSION
- 2006.08.02
- SANKYO COMMENCES PATENT LITIGATION AGAINST BENICAR® ANDA FILING IN THE UNITED STATES
